逆转T细胞耗竭在肿瘤免疫治疗中研究进展  

Research progress of reversing T cell depletion in tumor immunotherapy

作　　者：刘盼[1] 马敏婷 魏素菊[1] LIU Pan;MA Min-Ting;WEI Su-Ju(Hebei Province,4th Hospital,Hebei Medical University,Shijiazhuang 050001,China)

机构地区：[1]河北医科大学第四医院,石家庄050001

出　　处：《中国免疫学杂志》2020年第5期639-640,F0003,F0004,共4页Chinese Journal of Immunology

摘　　要：近年来随着肿瘤免疫治疗的深入研究,PD-1/PD-L1免疫抑制剂在临床试验及临床实际抗肿瘤应用中取得突破性进展,但仍有临床耐药及部分患者无效的问题,PD-1/PD-L1免疫抑制剂抗肿瘤机制主要为改善抗肿瘤免疫应答,逆转T细胞耗竭,增强T细胞抗肿瘤免疫反应。本文以逆转T细胞耗竭最新研究及进展应用于肿瘤免疫治疗作一综述,为临床治疗提供参考。In recent years,with the in-depth study of tumor immunotherapy,PD-1/PD-L1 immunosuppressant has made a breakthrough in clinical trials and clinical application of anti-tumor,but there are still problems of clinical drug resistance and ineffective in some patients.The main anti-tumor mechanism of PD-1/PD-L1 immunosuppressant is to improve the anti-tumor immune response,reverse the depletion of T cells,and enhance the anti-tumor immune response of T cells.In this paper,we review the latest research and progress of T cell depletion reversal in tumor immunotherapy,and provide reference for clinical treatment.

关 键 词：T细胞耗竭 PD-1/PDL-1 免疫治疗 

分 类 号：R730.3[医药卫生—肿瘤]